HSKA 16.20 Heska Corp $HSKA Hit a 52 week high of 16.50

New Post Public Reply Private Reply Replies (0) Message Board

Nov 10, 2014 at 11:36 AM

HSKA 16.20 Heska Corp $HSKA Hit a 52 week high of 16.50 Currently at 16.20 +0.30 +1.89% With a day low of 16.20 and a total volume of 6,282.

HSKA Heska Corp Recent Headline News

Achillion Pharmaceuticals Slumps: ACHN Plunges 15.6% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 7:34AM CST
Achillion Pharmaceuticals (ACHN) fell nearly 16% in the last trading session amid huge volumes, reversing its recent trend, as the stock is now up nearly 3% in the past one month.
AGEN: 3.02 (unch), HSKA: 15.87 (-0.03), ACHN: 12.21 (+2.10), AMAG: 34.83 (-0.12)

Heska Announces Investor Day in New York City
PR Newswire - Tue Nov 04, 8:00AM CST
Heska Corporation (NASDAQ: HSKA - News; "Heska" or the "Company"

, a provider of advanced veterinary diagnostic and other specialty veterinary products, today announced the Company will conduct an Investor Day, from 9 a.m. to noon (EST) on Friday, November 14, 2014. The event will be at the Nasdaq MarketSite in Times Square, located at One Liberty Plaza, 165 Broadway, in New York City.
HSKA: 15.87 (-0.03)

Qiagen Q3 Earnings, Revenues in Line; Outlook Revised - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 1:50PM CDT
Qiagen's (QGEN) strategic collaborations, test menu expansions and moderately balanced international expansion will likely drive growth over time.
BIIB: 325.51 (+4.76), HSKA: 15.87 (-0.03), ILMN: 189.63 (+3.28), QGEN: 23.75 (+0.27)

Can the Rally in Heska (HSKA) Shares Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 8:06AM CDT
Can the Rally in Heska (HSKA) Shares Continue?
HSKA: 15.87 (-0.03)

Heska Reports 24% Revenue Growth, $0.08 Per Share for the Third Quarter of 2014
PR Newswire - Wed Oct 29, 8:00AM CDT
Heska Corporation (NASDAQ: HSKA; "Heska" or the "Company"

, a provider of advanced veterinary diagnostic and other specialty veterinary products, today reported financial results for its third quarter ended September 30, 2014.
HSKA: 15.87 (-0.03)

Heska Signs Distribution Agreement with Henry Schein Animal Health
PR Newswire - Wed Oct 29, 7:45AM CDT
Heska Corporation (NASDAQ: HSKA - News; "Heska" or the "Company"

, a provider of advanced veterinary diagnostic and other specialty veterinary products, announced today a new distribution agreement with Henry Schein Animal Health, the largest companion animal health distribution company in the U.S. Henry Schein Animal Health will market and promote Heska's full line of hematology and chemistry instruments and affiliated consumables, effective immediately.
HSKA: 15.87 (-0.03), HSIC: 130.04 (+1.20)

Webcast Alert: Heska Announces Third Quarter 2014 Earnings Conference Call Webcast
PR Newswire - Tue Oct 28, 3:30PM CDT
Heska Corporation (Nasdaq: HSKA) announces the following Webcast:
HSKA: 15.87 (-0.03)

Repros Therapeutics (RPRX) Worth Watching: Stock Up 17% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Sep 29, 8:46AM CDT
Repros Therapeutics (RPRX) was a big mover last session, with shares surging almost 17% on the day.
CBM: 23.26 (+0.60), HSKA: 15.87 (-0.03), GILD: 108.10 (+1.65), RPRX: 9.24 (-0.88)

Cyclacel Pharmaceuticals (CYCC) in Focus: Stock Jumps 5.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Sep 29, 8:21AM CDT
Cyclacel Pharmaceuticals, Inc. (CYCC) was a big mover last session, as the company saw its shares rise by over 5% on the day.
HSKA: 15.87 (-0.03), CBM: 23.26 (+0.60), CYCC: 3.20 (+0.11), GILD: 108.10 (+1.65)

Myriad Genetics Poised on Strong myRisk, Overseas Results - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 26, 2:20PM CDT
Currently, Myriad Genetics (MYGN) is financing 13 Phase III clinical trials with flagship product BracAnalysis CDx in six different indicated patient populations.
MYGN: 33.87 (-1.02), HSKA: 15.87 (-0.03), CBM: 23.26 (+0.60), GILD: 108.10 (+1.65)

Qiagen's Molecular Diagnostics, Global Market Show Strength - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 26, 1:50PM CDT
On Sep 25, we issued an updated research report on Qiagen N.V. (QGEN).
HSKA: 15.87 (-0.03), GILD: 108.10 (+1.65), ANTH: 1.82 (-0.02), QGEN: 23.75 (+0.27)

Rexahn Pharmaceuticals (RNN) Jumps: Stock Gains 10.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Sep 26, 8:25AM CDT
Rexahn Pharmaceuticals (RNN) was a big mover last session, as the company saw its shares rise over 10% on the day.
RNN: 0.70 (-0.01), HSKA: 15.87 (-0.03), CBM: 23.26 (+0.60), GILD: 108.10 (+1.65)

Dynavax (DVAX) Jumps: Stock Moves 6.7% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Sep 22, 8:46AM CDT
Dynavax (DVAX) was a big mover last session, with shares rising nearly 7% on the day.
DVAX: 15.83 (+14.24), HSKA: 15.87 (-0.03), GILD: 108.10 (+1.65), ILMN: 189.63 (+3.28)

Alder Biopharmaceuticals (ALDR) in Focus: Stock Up 5.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Sep 18, 7:44AM CDT
Alder Biopharmaceuticals Inc. (ALDR) was a big mover last session, as the company saw its shares rise over 5% on the day.
ALDR: 16.86 (+0.29), CBM: 23.26 (+0.60), HSKA: 15.87 (-0.03), ILMN: 189.63 (+3.28)

Is Illumina (ILMN) a Buy on Solid Q2, Strategic Road Map? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 16, 2:30PM CDT
On Sep 16, 2014, we issued an updated research report on life sciences company Illumina Inc. (ILMN).
HSKA: 15.87 (-0.03), GILD: 108.09 (+1.64), AMGN: 162.93 (+2.68), ILMN: 189.63 (+3.28)

Dendreon (DNDN) in Focus: Stock Up 9.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Sep 16, 7:44AM CDT
Dendreon Corp. (DNDN) was a big mover last session, as the company saw its shares rise over 9% on the day
CBM: 23.26 (+0.60), HSKA: 15.87 (-0.03), DNDN: 0.24 (-0.70), ILMN: 189.63 (+3.28)

Cytokinetics (CYTK) Looks Strong: Stock Gains 17.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Sep 11, 7:44AM CDT
Cytokinetics (CYTK) as a big mover last session, as the company saw its shares surge over 17 % on the day
CYTK: 4.24 (+0.14), CBM: 23.26 (+0.60), HSKA: 15.87 (-0.03), ILMN: 189.63 (+3.28)

Synthetic Biologics (SYN) Looks Strong: Stock Gains 13.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Sep 02, 7:44AM CDT
Synthetic Biologics (SYN) was a big mover last session, as the company saw its shares gain nearly 14% on the day
SYN: 1.47 (-0.02), CBM: 23.26 (+0.60), HSKA: 15.87 (-0.03), ILMN: 189.63 (+3.28)

China Biologic Products, Inc. (CBPO) Rises: Stock Jumps 7.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Aug 27, 8:32AM CDT
China Biologic Products, Inc. (CBPO) was a big mover last session, as the company saw its shares rise more than 7% on the day.
CBPO: 64.29 (-4.61), HSKA: 15.87 (-0.03), CBM: 23.26 (+0.60), GILD: 108.09 (+1.64)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Regeneron: Investors Face Class Action Over Study Flaws

Regeneron Investors Grit Teeth Amid Lawsuit Drama The gloves are off in the pharmaceutical battleground, folks. Investors who thought they were riding the big wave with Regeneron Pharmaceuticals (NASDAQ: REGN) are now staring down the barrel of a class action lawsuit. It seems the company’s been caught in a storm of legal action following allegations of misleading...

Connected Retail Security: Rising Risks and Fragmented Roles

Cyber Threats in the Connected Retail Landscape The retail world isn't what it used to be. Walk into a store today, and you're greeted not just by products but a web of interconnected systems screaming for attention. Sure, you've got your old-school POS systems humming along, but they're just one brittle cog in a rattling machine of IoT devices, cloud platforms, and...

King Risk Partners Expands Mid-Atlantic Presence Boldly

King Risk Partners Grows with New Jersey Acquisition You don't get far in the insurance game without making some bold moves, and King Risk Partners just made a big one—sweeping into New Jersey. They've snagged Conover Beyer Associates Insurance, a firm that's been around longer than some European countries. It's not every day you buy a piece of history, but that's...

Cheetah Mobile Q2 2026 Results: What's on the Horizon?

Anticipation Builds for Cheetah Mobile's Q2 Results Nine rounds into the slugfest that is the 2026 market, we've got another round approaching—Cheetah Mobile is set to unveil its second quarter numbers on September 11th. This isn't some sleepy, run-of-the-mill report either; NYSE:CMCM is a player with skin in the IT game, and commentators are eyeing the clock with...

Long Island's JCC Boosted by Manes Family Legacy

Unpacking a Monumental Gift to Long Island's Jewish Community Right out of the gate, this is a big one for the folks over at the Mid Island Y JCC in Plainview, Long Island. They've just hit the jackpot with a historic naming gift, transforming the place into the Manes JCC. Now, why does this matter to anyone keeping tabs on the nonprofit world? Because gifts like these...

Missouri American Water's $34.5M Neosho Acquisition Outline

Missouri American Water Expands in Neosho, Missouri Well, buckle up because Missouri American Water just sealed the deal to take over Neosho's water and wastewater systems. This acquisition cost them a cool $34.5 million and is bringing 5,400 water and another 5,400 wastewater customers into the fold. Plus, they're welcoming onboard 25 local workers who've been in the...

Jim Morey Joins Pickleman's to Drive Expansion

Jim Morey: Catalyst for Pickleman's Ambitious Dreams You ever heard of a sandwich joint ready to take on the big leagues? Because that's just what Pickleman's Gourmet Café is banking on with their latest move—tapping none other than Jim Morey for their executive advisory board. And let me tell ya, this ain't some run-of-the-mill hire. We're talking about a guy who's...

Stronghold's Unfulfilled Promise May Cost Coachella Millions

Coachella's Taxpayer Gamble City of Coachella decided to pull the plug on a deal that could've kept wallets fuller around here. Stronghold Power Systems officials say their shot at leading the municipal utility project got snagged by some bureaucratic red tape or maybe something else. Procurement Process: Two-year-long selection. Investment by Stronghold: $8 million of...

LaserPecker Debuts U1: Innovations in UV Laser Engraving

An Eye on the Future with LaserPecker's U1 This ain't your typical innovation announcement. LaserPecker is shifting the sands with their latest release, the U1, at IFA 2026 in Berlin. For anyone sick of struggling with transparent materials like glass and crystal, this thing promises to be a game-changer, boasting cutting-edge technology in UV laser engraving. While...

Smithfield's Foreign Lobbying Interests Unveiled Amid Uproar

A Behind-the-Scenes Drama Over Lobbying Disclosure Something's fishy beneath the surface of Smithfield Foods' recent lobbying debacle. The Center for Responsible Food Business (CRFB) has turned the spotlight on some shady practices, and folks, it ain't pretty. Smithfield's lobbyists had been ducking disclosure rules apparently meant to keep track of foreign influence. Who...